Low Testosterone: A New Clue in Prostate Cancer Surveillance?
For men opting for active surveillance of early-stage prostate cancer, a new study suggests a common blood test – testosterone level – could be a critical indicator of risk. Researchers at The University of Texas MD Anderson Cancer Center have found a link between low testosterone and a significantly higher likelihood of cancer progression to a more aggressive state.
Rethinking Testosterone’s Role in Prostate Cancer
Traditionally, high testosterone has been considered a potential driver of prostate cancer growth. However, this research challenges that assumption, suggesting that low testosterone may actually signal a more dangerous trajectory for cancers under surveillance. The study, published in The Journal of Urology, found that men with testosterone levels at or below 300 ng/dL were 60% more likely to experience progression to Grade Group 3 – a more aggressive form of the disease.
Active Surveillance and the Need for Better Biomarkers
Active surveillance is a common approach for men with early-stage prostate cancer, allowing them to avoid immediate treatment like surgery or radiation and their associated side effects. However, a key challenge is identifying which patients are at higher risk of progression. This study suggests baseline testosterone levels could be a valuable clinical marker to help doctors better stratify risk and tailor monitoring strategies.
How the Study Was Conducted
Researchers retrospectively analyzed data from 924 men enrolled in an active surveillance program between 2001 and 2024. The median follow-up period for those who did not experience progression was 46.1 months. The study focused on progression to Grade Group 2 or Grade Group 3 disease. Even after accounting for factors like age, prostate-specific antigen (PSA) density, and biopsy tumor volume, the association between low testosterone and Grade Group 3 progression remained statistically significant.
What Does This Mean for Patients?
This finding doesn’t mean low testosterone causes aggressive prostate cancer. Rather, it suggests that low levels may indicate an existing cancer environment that is already more prone to aggressive behavior. For men undergoing active surveillance, this could mean more frequent biopsies, scans, or blood checks to closely monitor for any changes.
The 300 ng/dL Threshold: A Clinically Relevant Cutoff
Interestingly, the 300 ng/dL threshold for low testosterone aligns with existing clinical guidelines used by urologists. Approximately 29% of the men in the study started with testosterone levels at or below this cutoff. This makes it a readily available and easily measurable biomarker for clinicians.
Hormones and Cancer: A Complex Relationship
Prostate tumors are known to respond to androgens, like testosterone. While hormone-blocking treatment can be effective in slowing cancer growth, this study highlights a more nuanced relationship. It suggests that low circulating hormones may be a sign of a cancer that is already acting aggressively, rather than a cause of that aggression.
Future Research Directions
Researchers emphasize the need for further studies that prospectively follow men, measuring hormone levels on a regular schedule. Repeated morning testosterone tests are crucial, as levels fluctuate throughout the day. Incorporating newer imaging and biopsy techniques could help determine if this association holds true in current clinical practice.
FAQ
- Does low testosterone cause prostate cancer? No, the study did not find that low testosterone causes prostate cancer. It suggests it’s associated with a higher risk of progression in men already on active surveillance.
- What is active surveillance? Active surveillance is a strategy for managing early-stage prostate cancer that involves close monitoring with delayed treatment unless the cancer worsens.
- What is Grade Group 3? Grade Group 3 indicates a more aggressive form of prostate cancer based on biopsy results.
- Should I get my testosterone levels checked if I have prostate cancer? Talk to your doctor about whether testosterone testing is appropriate for you, especially if you are on active surveillance.
—–
Desire to stay informed about the latest in men’s health? Subscribe to our newsletter for exclusive content and updates.
Explore more health insights on EarthSnap, brought to you by Eric Ralls and Earth.com.
Worth a look
